An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab

Osteoporosis is responsible for a significant burden both individually and socially, but is readily treated with antiresorptive agents and mineral supplementation. However, long-term usage of these agents, notably bisphosphonates, is rarely associated with atypical fractures. Denosumab is a monoclon...

Descripción completa

Detalles Bibliográficos
Autores principales: Villiers, J., Clark, D. W., Jeswani, T., Webster, S., Hepburn, A. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893843/
https://www.ncbi.nlm.nih.gov/pubmed/24490096
http://dx.doi.org/10.1155/2013/249872
_version_ 1782299758779432960
author Villiers, J.
Clark, D. W.
Jeswani, T.
Webster, S.
Hepburn, A. L.
author_facet Villiers, J.
Clark, D. W.
Jeswani, T.
Webster, S.
Hepburn, A. L.
author_sort Villiers, J.
collection PubMed
description Osteoporosis is responsible for a significant burden both individually and socially, but is readily treated with antiresorptive agents and mineral supplementation. However, long-term usage of these agents, notably bisphosphonates, is rarely associated with atypical fractures. Denosumab is a monoclonal antibody that reduces osteoclast activity and thus increases bone mineral density. In this case report, we present a 78-year-old woman with a background of rheumatoid arthritis and osteoporosis who presented with an atypical diaphyseal femoral fracture.
format Online
Article
Text
id pubmed-3893843
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38938432014-02-02 An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab Villiers, J. Clark, D. W. Jeswani, T. Webster, S. Hepburn, A. L. Case Rep Rheumatol Case Report Osteoporosis is responsible for a significant burden both individually and socially, but is readily treated with antiresorptive agents and mineral supplementation. However, long-term usage of these agents, notably bisphosphonates, is rarely associated with atypical fractures. Denosumab is a monoclonal antibody that reduces osteoclast activity and thus increases bone mineral density. In this case report, we present a 78-year-old woman with a background of rheumatoid arthritis and osteoporosis who presented with an atypical diaphyseal femoral fracture. Hindawi Publishing Corporation 2013 2013-12-07 /pmc/articles/PMC3893843/ /pubmed/24490096 http://dx.doi.org/10.1155/2013/249872 Text en Copyright © 2013 J. Villiers et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Villiers, J.
Clark, D. W.
Jeswani, T.
Webster, S.
Hepburn, A. L.
An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab
title An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab
title_full An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab
title_fullStr An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab
title_full_unstemmed An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab
title_short An Atraumatic Femoral Fracture in a Patient with Rheumatoid Arthritis and Osteoporosis Treated with Denosumab
title_sort atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893843/
https://www.ncbi.nlm.nih.gov/pubmed/24490096
http://dx.doi.org/10.1155/2013/249872
work_keys_str_mv AT villiersj anatraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT clarkdw anatraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT jeswanit anatraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT websters anatraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT hepburnal anatraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT villiersj atraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT clarkdw atraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT jeswanit atraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT websters atraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab
AT hepburnal atraumaticfemoralfractureinapatientwithrheumatoidarthritisandosteoporosistreatedwithdenosumab

Ejemplares similares